A detailed history of Woodline Partners LP transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Woodline Partners LP holds 1,544,287 shares of SNDX stock, worth $29.8 Million. This represents 0.35% of its overall portfolio holdings.

Number of Shares
1,544,287
Previous 1,544,216 -0.0%
Holding current value
$29.8 Million
Previous $33.4 Million 10.14%
% of portfolio
0.35%
Previous 0.38%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$19.71 - $24.57 $1,399 - $1,744
71 Added 0.0%
1,544,287 $36.8 Million
Q4 2023

Feb 14, 2024

BUY
$11.39 - $21.67 $17.2 Million - $32.7 Million
1,510,149 Added 4432.88%
1,544,216 $33.4 Million
Q3 2023

Nov 14, 2023

SELL
$14.52 - $21.77 $8.4 Million - $12.6 Million
-578,249 Reduced 94.44%
34,067 $494,000
Q2 2023

Aug 14, 2023

BUY
$19.35 - $22.31 $11.8 Million - $13.7 Million
612,316 New
612,316 $12.8 Million
Q3 2022

Nov 14, 2022

BUY
$18.51 - $24.79 $14.6 Million - $19.6 Million
789,273 New
789,273 $19 Million
Q1 2022

May 16, 2022

SELL
$14.84 - $22.15 $4.61 Million - $6.87 Million
-310,377 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$15.23 - $22.47 $4.13 Million - $6.09 Million
-270,931 Reduced 46.61%
310,377 $6.79 Million
Q3 2021

Nov 15, 2021

BUY
$13.87 - $19.8 $5.18 Million - $7.4 Million
373,496 Added 179.73%
581,308 $11.1 Million
Q2 2021

Aug 16, 2021

BUY
$13.42 - $25.18 $2.79 Million - $5.23 Million
207,812 New
207,812 $3.57 Million
Q1 2021

May 17, 2021

SELL
$19.28 - $24.59 $1.5 Million - $1.91 Million
-77,699 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$15.1 - $26.44 $1.17 Million - $2.05 Million
77,699 New
77,699 $1.73 Million

Others Institutions Holding SNDX

About Syndax Pharmaceuticals Inc


  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $1.09B
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.